Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

[Neurofilament light chain as a tool for assessing disease activity and treatment response in Multiple Sclerosis].

Fortschritte der Neurologie-Psychiatrie·2026

Same author

From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.

Journal of neurology·2026

Same author

Are Traditional Registries Becoming Obsolete in the Modern Digital Health Ecosystem?

Journal of medical Internet research·2026

Same author

Exploring attitudes and acceptance of artificial intelligence in multiple sclerosis from the patient perspective.

PLOS digital health·2026

Same author

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Therapeutic advances in neurological disorders·2026

Same author

Inpatient care for people with multiple sclerosis - a secondary data analysis in Germany between 2019 and 2024.

Neurological research and practice·2026

Search research articles

Related Experiment Video

Updated: Jul 5, 2025

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

[Current and innovative Approaches to Multiple Sclerosis Therapy].

Hernan Inojosa, Tjalf Ziemssen

Fortschritte Der Neurologie-Psychiatrie

|January 25, 2024

Summary

Multiple Sclerosis (MS) management involves dynamic immunotherapies. Personalized treatment selection requires considering early intervention, escalation vs. induction strategies, and patient-specific factors for optimal outcomes.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Related Experiment Videos

Last Updated: Jul 5, 2025

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Area of Science:

Neurology
Immunology
Pharmacology

Context:

The management of Multiple Sclerosis (MS) is rapidly evolving with numerous approved immunotherapies and ongoing clinical trials.
Advances in understanding MS pathophysiology and diagnostic criteria have led to the development of more targeted disease-modifying therapies (DMTs).

Purpose:

To provide a comprehensive overview of current immunotherapies for personalized MS treatment.
To discuss practical insights and considerations for applying these therapies effectively.

Summary:

The review covers over 21 approved immunotherapeutic options for MS, highlighting the increasing complexity in selecting appropriate treatments.
Key discussion points include the importance of early intervention, differentiating between escalation and induction therapeutic approaches, and identifying patient groups that benefit from high-efficacy treatments.

Impact:

Emphasizes a patient-centered approach to treatment decision-making, integrating factors like comorbidities, family planning, administration preferences, and potential side effects.
Aims to guide clinicians in navigating the complex landscape of MS immunotherapies for tailored patient care.